Kiora Pharmaceuticals, Inc. (KPRX)
NASDAQ: KPRX · Real-Time Price · USD
3.470
-0.040 (-1.14%)
Feb 21, 2025, 4:00 PM EST - Market closed
Kiora Pharmaceuticals Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Kiora Pharmaceuticals stock has a target of 10, which predicts an increase of 188.18% from the current stock price of 3.47.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 12, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for Kiora Pharmaceuticals is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +188.18% | Nov 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +188.18% | Aug 22, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $2 → $10 | Strong Buy | Maintains | $2 → $10 | +188.18% | Jul 23, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +418.73% | May 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 | Strong Buy | Maintains | $18 | +418.73% | Mar 27, 2024 |
Financial Forecast
Revenue This Year
17.10M
Revenue Next Year
3.06M
from 17.10M
Decreased by -82.10%
EPS This Year
0.88
from -24.25
EPS Next Year
-2.54
from 0.88
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 18.4M | 6.3M | 1.6M | |||
| Avg | 17.1M | 3.1M | 1.5M | |||
| Low | 15.7M | n/a | 1.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | -63.1% | -48.5% | |||
| Avg | - | -82.1% | -50.0% | |||
| Low | - | - | -52.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 1.34 | -2.34 | -2.67 | |||
| Avg | 0.88 | -2.54 | -2.59 | |||
| Low | 0.44 | -2.70 | -2.49 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.